Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.53 |
| ▸ | EBP | Q15125 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.48 |
| ▸ | GBA1 | P04062 | 2/20 | 0.45 |
| ▸ | GLB1 | P16278 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20940072 | 0.77 | GUSB (0.60) | GUSBEBPSIGMAR1GBA1GLB1 | |
| SCHEMBL19781522 | 0.77 | SAT1 (0.38) | GNAI3GNAO1GNAI1 | |
| SCHEMBL19880464 | 0.76 | GNAI3 (0.41) | GUSBGNAI3GNAO1GNAI1 | |
| SCHEMBL24261162 | 0.73 | BCHE (0.51) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25958547 | 0.73 | GUSB (0.55) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL11460191 | 0.72 | GUSB (0.70) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL17350929 | 0.72 | GUSB (0.70) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL28637415 | 0.72 | GUSB (0.84) | GUSBEBPSIGMAR1GBA1GLB1 | |
| SCHEMBL1859342 | 0.72 | GUSB (0.84) | GUSBEBPSIGMAR1GBA1GLB1 | |
| SCHEMBL23695777 | 0.71 | EBP (0.38) | GUSBEBPSIGMAR1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | GUSB 1523/4885EBP 1020/4885SIGMAR1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.